VORTIOXETINE
Clinical safety rating: safe
Animal studies have demonstrated safety
Vortioxetine is a multimodal antidepressant that acts as a serotonin reuptake inhibitor (SRI), 5-HT1A receptor agonist, 5-HT1B receptor partial agonist, and antagonist at 5-HT3, 5-HT1D, and 5-HT7 receptors. This complex pharmacology enhances serotonergic activity in specific brain regions while modulating other neurotransmitter systems.
| Metabolism | Primarily metabolized by CYP2D6, with minor contributions from CYP3A4 and CYP2C9. Also undergoes oxidation followed by glucuronide conjugation. |
| Excretion | Vortioxetine is extensively metabolized, and the majority of the dose is excreted in urine (approximately 59%) as metabolites, with about 26% excreted in feces as unchanged drug or metabolites. Renal excretion of unchanged vortioxetine is negligible (<1%). |
| Half-life | The terminal elimination half-life of vortioxetine is approximately 66 hours (range 59–75 hours), supporting once-daily dosing. Steady-state concentrations are achieved within 14 days. |
| Protein binding | Approximately 98–99% bound to plasma proteins, primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | The apparent volume of distribution is approximately 2600 L (or ~37 L/kg for a 70 kg individual), indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability is approximately 75% (range 60–90%) and is not significantly affected by food. |
| Onset of Action | Therapeutic effects (antidepressant response) are typically observed within 2–4 weeks of starting oral therapy, although some improvement may be seen as early as 2 weeks. No other routes are clinically available. |
| Duration of Action | Due to its long half-life, the pharmacodynamic effect persists for several days after discontinuation; gradual dose tapering is recommended to avoid withdrawal symptoms. |
| Molecular Weight | 298.36 |
10 mg orally once daily; may increase to 20 mg once daily. Maximum dose 20 mg/day.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (eGFR >= 30 mL/min). Insufficient data for severe renal impairment (eGFR < 30 mL/min); use with caution. |
| Liver impairment | Child-Pugh A (mild): no dose adjustment. Child-Pugh B (moderate): maximum dose 10 mg once daily. Child-Pugh C (severe): not recommended. |
| Pediatric use | Not approved for use in pediatric patients (safety and efficacy not established). |
| Geriatric use | No dose adjustment required based solely on age; consider lower starting dose of 5 mg once daily due to increased sensitivity and potential for hyponatremia. |
| 1st trimester | Limited human data; animal studies show no teratogenicity but risk of poor neonatal adaptation if used late in pregnancy. Avoid unless benefit outweighs risk. |
| 2nd trimester | May be used with caution; monitor for maternal and fetal effects. Risk of preterm birth and low birth weight reported. |
| 3rd trimester | Use with caution; risk of neonatal withdrawal syndrome (irritability, feeding difficulties, respiratory distress) and persistent pulmonary hypertension of the newborn (PPHN). Taper if possible. |
Clinical note
MAOIs can cause serotonin syndrome Can cause nausea and increased risk of bleeding.
| Placental transfer | Vortioxetine crosses the placenta; animal studies show fetal exposure with maternal doses. Human data limited but demonstrates transfer with potential for neonatal effects. |
| Breastfeeding | Vortioxetine is excreted into human milk in low amounts; relative infant dose estimated <5%. Monitor infant for drowsiness, poor feeding, and weight gain. Use with caution, especially in preterm or low-weight infants. |
■ FDA Black Box Warning
Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies. Monitor closely for clinical worsening, suicidality, or unusual changes in behavior.
| Common Effects | Nausea |
| Serious Effects |
Hypersensitivity to vortioxetine or any excipientConcomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI useConcomitant use with linezolid or intravenous methylene blue
| Precautions | Activation of mania/hypomania, Hyponatremia (SIADH), Serotonin syndrome, Angle-closure glaucoma, Sexual dysfunction, Increased bleeding risk (especially with NSAIDs/anticoagulants), Cognitive and motor impairment |
| Food/Dietary | No significant food interactions. Grapefruit and grapefruit juice do not affect vortioxetine metabolism. Avoid excessive alcohol consumption due to potential additive CNS effects. |
Loading safety data…
| Lactation Rating | L2 (Probably Compatible) |
| Teratogenic Risk | Pregnancy category not formally assigned; data limited. Animal studies show no major teratogenicity at clinically relevant doses, but fetal exposure occurs. First trimester: risk of major malformations not significantly increased based on small human studies; second and third trimesters: potential risk of poor neonatal adaptation syndrome including respiratory distress, feeding difficulties, irritability, and muscle tone abnormalities due to serotonergic effects. |
| Fetal Monitoring | Monitor for signs of serotonin syndrome (e.g., hyperthermia, rigidity, myoclonus) in mother. Assess fetal growth via ultrasound. Monitor neonate for poor neonatal adaptation syndrome (including respiratory distress, feeding difficulties, irritability, tremor, and hypotonia) for 2-4 days postpartum. |
| Fertility Effects | No specific human studies on fertility; animal studies showed no significant impairment of fertility at exposures up to 2.5 times the maximum recommended human dose. However, hyperprolactinemia may occur with SSRIs, potentially affecting gonadal function, though not specifically reported for vortioxetine. |
| Clinical Pearls | Vortioxetine is a multimodal antidepressant that acts as a serotonin reuptake inhibitor, 5-HT1A agonist, 5-HT1B partial agonist, and 5-HT3 and 5-HT7 antagonist. It has a linear pharmacokinetic profile and is dosed at 5-20 mg once daily. Start at 5 mg and titrate by 5 mg increments weekly. Efficacy in cognitive dysfunction (e.g., processing speed) is a distinguishing feature. Avoid in patients with serotonin syndrome risk; use with caution in hepatic impairment (Child-Pugh B: dose adjustment recommended). Vortioxetine has low potential for sexual dysfunction and weight gain compared to other SSRIs/SNRIs. Therapeutic response may take 2-4 weeks. |
| Patient Advice | Take vortioxetine once daily at the same time each day, with or without food. · Do not stop abruptly; taper under medical supervision to avoid withdrawal symptoms. · May improve cognitive symptoms like concentration and memory in addition to mood. · Report any symptoms of serotonin syndrome (e.g., agitation, hallucinations, rapid heart rate, fever, muscle stiffness). · Avoid alcohol unless cleared by your doctor, as it may increase dizziness or drowsiness. · May cause nausea, especially at the start; this often improves over time. · Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding. · Monitor for worsening depression or suicidal thoughts, especially in young adults. |